title: Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Commentary.
authors.affiliation: Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, New York, USA. deborah_levy@urmc.rochester.edu
authors.forename: Deborah R
authors.initials: DR
authors.lastname: Levy
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Pearson
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D012307:Risk Factors
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors